AT CDTT Stenting Femoral vein 60% 100% 2/26 External iliac vein 60% 100% 6/26 Common iliac vein 50% 80% 8/26 IVC 25% 60% - Follow up: Mean e 1 year (8 months e 19 months); Recurrence of DVT e 2/26; PTS e 0/26 and Pulmonary Embolism e 0/26. Conclusion: Interventional approach for acute DVT is successful, promising and feasible. Rapid removal and lysis results in pre- serving venous valve functions and reducing the incidence of PTS. Stem cell augmentation for cardiovascular risk in Rheumatoid Arthritis: STAR study A. Syngle, N. Garg, P. Krishan, I. Verma Healing Touch City Clinic Chandigarh, Punjabi University, Patiala, India Background: Bone marrow derived stem cells, endothelial pro- genitor cells (EPCs), protect against atherosclerotic vascular damage. However, EPCs are depleted in RA and contribute to the enhanced cardiovascular (CV) risk. Therapeutic potential of aug- menting EPCs to treat the heightened CV risk of RA has not yet been exploited. We aimed to investigate the effect of rosuvastatin on EPCs population, endothelial dysfunction, nitrite, adhesion molecules and on markers of inflammation in RA. Methods: 50 RA patients, randomized to receive 24 weeks of treatment with rosuvastatin (10mg/day, n¼25) or placebo (n¼25) as an adjunct to existing stable antirheumatic drugs. EPCs (CD34+/ CD133+) were quantified by Flow Cytometry. Flow mediated dilatation (FMD) was assessed by AngiodefenderTM (Everest Genomic Ann Arbor, United States). Inflammatory measures included DAS28, CRP, ESR, Pro-inflammatory cytokines (TNF-a, IL- 6 and IL-1), levels of serum nitrite, lipids and adhesion molecules (ICAM-1 and VCAM-1) was done at baseline and after treatment. Results: At baseline, inflammatory measures, pro-inflammatory cytokines, adhesion molecules and nitrite levels were elevated and EPCs and endothelial function were impaired among both groups. At 24 wks: DAS28, ESR, CRP, TNF-a, IL-6, nitrite and ICAM- 1 improved significantly in rosuvastatin group. EPCs increased significantly after treatment with rosuvastatin as compared with placebo. FMD improved significantly in the rosuvastatin group. Rosuvastatin exerted positive effect on lipids. Significant inverse correlation observed between EPCs and CRP, TNF-a, ICAM-1and FMD after rosuvastatin treatment. Conclusion: First study to show that rosuvastatin augments EPCs population in RA mediated by lowering the cytokine levels, which downregulates adhesion molecule, CRP and nitric oxide produc- tion. This defines a novel mechanism of rosuvastatin treatment in RA: the augmentation of EPCs with improvement in inflammatory disease activity and endothelial dysfunction. New oral anticoagulants in atrial fibrillation L. Sumithra, S.S. Iyengar, V. Subash Chandra, G. Sridhara, Roshan D'silva Manipal Hospital, India Background: Atrial fibrillation (AF) is a common arrhythmia, and is an important cause of stroke. Risk of stroke and bleeding need to be assessed before initiating anticoagulant treatment. New oral anticoagulants (NOACs) are available now as an alternative to vitamin K antagonists (VKA). Objective: Our objective was to study the incidence of valvar AF versus nonvalvar AF, the scores for risk of stroke and bleeding and the use of NOACs in a tertiary case hospital. Methods: Cases of atrial fibrillation hospitalized or seen in out patient over a period of two years were studied. CHA2DS2VASc and HASBLED scores were applied to all cases of nonvalvar AF. Creatinine clearance was calculated by Cockroft formula. Results: There were 60 patients of AF, 30 being male. Mean age was 66.6 years overall, 62.6 years for male and 70.6 for female patients. 43 (71.6 %) patients had nonvalvar AF and 17 (28 .4 %) had valvar AF. OF 17 cases of valvular AF, 04 had prosthetic valve and all were on VKA. For the 43 patients of nonvalvar AF, the mean CHA2DS2VASc score was 2.8 and the mean HASBLED score was 1.5. Fifteen pa- tients received dabigatran. Of these 15 patents, one shifted from VKA to dabigatran as she found frequent INR monitoring incon- venient. 35 opted for VKA for economic reasons and 5 declined to have any anticoagulation. In one patient, oral anticoagulation was not started since he had subdural hematoma. In four patients, oral anticoagulation was not indicated as the CHA2DS2VASc score was 0. Amongst 15 patients who received dabigatran, 11 were on 110 mg twice a day dose because of age, renal dysfunction and body weight, 4 were on 150 mg twice a day. All these patients tolerated dabigatran well. Conclusion: There were more nonvalvar AF cases than valvar AF and female patients were older. CHA2DS2VASc and HASBLED scores are easy to apply and help in decision making on initiation of oral anticoagulants in nonvalvar AF patients. Dabigatran is an attractive alternative to VKA to prevent stroke in nonvalvar AF. Cost, compliance, comorbidites and coadministration of other drugs may be constraints for the use of NOACs. To study Troponin T levels and its significance in relation to mortality and morbidity in acute ischemic stroke A. Lalchandani, Anand Kumar Singh, P. Paliwal, M. Godara, M. Naveen, T. Midha, A. Garg, A.N. Singh, P. Singh PG Institute of Medicine, GSVM Medical College, Kanpur, India Background: Troponin T levels have been shown to have a very good correlation with cardiac stroke or myocardial infarction. In this study Troponin T levels were evaluated in patients of acute ischemic stroke. It follows that Troponin T levels must have a correlation with morbidity and mortality in these patients (pt.). Methods: Pt of acute ischemic stroke confirmed by CT scan or MRI within 72 hr of stroke onset, admitted in medicine ward of L.L.R and associated hospital in G.S.V.M medical college Kanpur and measurement of cTn T between 12-72 hr of stroke onset. There were 45 patients in study who were admitted over a period of January 2010 to September 2011. Results: 17.8% of patients in study show rise in troponin T (>0.01mcgm/dl) out of which 37.5% pt had poor outcome while indian heart journal 66 (2014) s1 es143 S120